Aurora Cannabis Inc. (ACB)
USD 4.24
(-5.15%)
USD 4.24
(-5.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 270.28 Million CAD | 15.86% |
| 2022 | 233.29 Million CAD | 5.4% |
| 2021 | 221.33 Million CAD | -9.75% |
| 2020 | 245.25 Million CAD | -12.07% |
| 2019 | 278.9 Million CAD | 12.49% |
| 2018 | 247.93 Million CAD | 349.2% |
| 2017 | 55.19 Million CAD | 205.51% |
| 2016 | 18.06 Million CAD | 1155.29% |
| 2015 | 1.43 Million CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | -100.0% |
| 2008 | 40.83 Thousand CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q1 | 63.41 Million CAD | 26.29% |
| 2023 Q2 | 64.41 Million CAD | 1.58% |
| 2023 Q3 | 67.41 Million CAD | 4.64% |
| 2023 FY | 270.28 Million CAD | 15.86% |
| 2022 Q3 | 72.13 Million CAD | 16.95% |
| 2022 Q4 | 50.21 Million CAD | -30.39% |
| 2022 Q2 | 61.67 Million CAD | 25.2% |
| 2022 Q1 | 49.26 Million CAD | -1.9% |
| 2022 FY | 233.29 Million CAD | 5.4% |
| 2021 Q4 | 50.21 Million CAD | -0.43% |
| 2021 Q1 | 60.1 Million CAD | 10.08% |
| 2021 FY | 221.33 Million CAD | -9.75% |
| 2021 Q2 | 60.58 Million CAD | 0.8% |
| 2021 Q3 | 50.43 Million CAD | -16.76% |
| 2020 Q4 | 54.6 Million CAD | -1.01% |
| 2020 Q1 | 67.81 Million CAD | -5.97% |
| 2020 Q2 | 67.67 Million CAD | -0.2% |
| 2020 FY | 245.25 Million CAD | -12.07% |
| 2020 Q3 | 55.16 Million CAD | -18.49% |
| 2019 Q3 | 75.52 Million CAD | 34.79% |
| 2019 Q4 | 72.11 Million CAD | -4.51% |
| 2019 Q2 | 56.02 Million CAD | -25.54% |
| 2019 Q1 | 75.24 Million CAD | -23.95% |
| 2019 FY | 278.9 Million CAD | 12.49% |
| 2018 Q4 | 98.94 Million CAD | 51.88% |
| 2018 FY | 247.93 Million CAD | 349.2% |
| 2018 Q1 | 29.67 Million CAD | 54.98% |
| 2018 Q2 | 54.17 Million CAD | 82.58% |
| 2018 Q3 | 65.14 Million CAD | 20.24% |
| 2017 Q1 | 8.24 Million CAD | 38.97% |
| 2017 Q4 | 19.14 Million CAD | 18.93% |
| 2017 FY | 55.19 Million CAD | 205.51% |
| 2017 Q3 | 16.1 Million CAD | 37.61% |
| 2017 Q2 | 11.7 Million CAD | 41.84% |
| 2016 Q3 | 5.17 Million CAD | 33.23% |
| 2016 Q2 | 3.88 Million CAD | 26.47% |
| 2016 FY | 18.06 Million CAD | 1155.29% |
| 2016 Q4 | 5.93 Million CAD | 14.69% |
| 2016 Q1 | 3.07 Million CAD | 151.75% |
| 2015 FY | 1.43 Million CAD | 0.0% |
| 2015 Q4 | 1.22 Million CAD | 456.51% |
| 2015 Q3 | 219.23 Thousand CAD | -95.06% |
| 2015 Q2 | 4.43 Million CAD | 0.0% |
| 2015 Q1 | - CAD | 100.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q4 | -18.5 Thousand CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q1 | - CAD | -100.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | -100.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q4 | 40.83 Thousand CAD | 0.0% |
| 2008 FY | 40.83 Thousand CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Theratechnologies Inc. | 81.76 Million USD | -230.562% |
| Harrow Health, Inc. | 130.19 Million USD | -107.6% |
| Dynavax Technologies Corporation | 232.28 Million USD | -16.358% |
| Biofrontera Inc. | 34.07 Million USD | -693.288% |
| Cronos Group Inc. | 88.84 Million USD | -204.23% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -2022.348% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 38.952% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -4049.759% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -583.347% |
| Radius Health, Inc. | 2.88 Billion USD | 90.622% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -736.557% |
| DURECT Corporation | 8.54 Million USD | -3061.921% |
| ProPhase Labs, Inc. | 44.38 Million USD | -508.96% |
| Safety Shot Inc | 202.67 Thousand USD | -133260.142% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 73.441% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -13915.111% |
| Alvotech | 91.43 Million USD | -195.602% |
| Assertio Holdings, Inc. | 152.06 Million USD | -77.736% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 55.511% |
| Rockwell Medical, Inc. | 83.61 Million USD | -223.256% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1021.834% |
| Procaps Group S.A. | 409.92 Million USD | 34.065% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 41.796% |
| SCYNEXIS, Inc. | 140.14 Million USD | -92.864% |
| Aytu BioPharma, Inc. | 81 Million USD | -233.672% |
| Viatris Inc. | 15.42 Billion USD | 98.248% |
| OptiNose, Inc. | 70.98 Million USD | -280.747% |
| SIGA Technologies, Inc. | 139.91 Million USD | -93.172% |
| Tilray Brands, Inc. | 788.94 Million USD | 65.741% |
| PetIQ, Inc. | 1.1 Billion USD | 75.473% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1021.834% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 85.677% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -2106.637% |
| Alimera Sciences, Inc. | 80.75 Million USD | -234.697% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 52.312% |
| Silver Spike Investment Corp. | 11.72 Million USD | -2205.732% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 37.6% |
| Journey Medical Corporation | 79.18 Million USD | -241.346% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -4542.099% |
| Alpha Teknova, Inc. | 36.68 Million USD | -636.782% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -1451.823% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -110.727% |
| PainReform Ltd. | - USD | -Infinity% |
| Cosmos Health Inc. | 53.37 Million USD | -406.363% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -866.567% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -20658.909% |
| Embecta Corp. | 1.12 Billion USD | 75.885% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Talphera, Inc. | 651 Thousand USD | -41417.819% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 59.957% |
| Incannex Healthcare Limited | 12 Thousand USD | -2252241.667% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -25009.601% |
| Shineco, Inc. | 9.8 Million USD | -2657.447% |
| Procaps Group, S.A. | 409.92 Million USD | 34.065% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 44.48% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -434.332% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 79.152% |
| Alvotech | 91.43 Million USD | -195.602% |
| Hempacco Co., Inc. | 4.04 Million USD | -6580.802% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 14.633% |
| Bright Green Corporation | 401.49 Thousand USD | -67219.317% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -132.332% |
| Kamada Ltd. | 144.75 Million USD | -86.711% |
| Indivior PLC | 1.09 Billion USD | 75.272% |
| Evoke Pharma, Inc. | 5.18 Million USD | -5117.145% |
| Flora Growth Corp. | 76.07 Million USD | -255.301% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -25009.601% |
| Evolus, Inc. | 202.08 Million USD | -33.746% |
| HUTCHMED (China) Limited | 837.99 Million USD | 67.747% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 58.057% |
| Akanda Corp. | 2.16 Million USD | -12412.708% |